Not Yet RecruitingNot Applicable

Real-World Study of Xeligekimab for Moderate to Severe Plaque Psoriasis(XP-Real)

China1,000 participantsStarted 2025-01-30

Plain-language summary

Xeligekimab Injection was approved in China on August 20, 2024, for treating adults with moderate to severe plaque psoriasis who are candidates for systemic treatment or phototherapy. Despite the promising efficacy and safety shown in the phase III clinical trial, real-world data is needed to further support clinical decisions for this patient group. This study aims to evaluate the effectiveness and safety of xeligekimab in real-world clinical settings for adults with moderate to severe plaque psoriasis.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients 18 years of age or older;
✓. Patients with a confirmed clinical diagnosis of moderate to severe plaque psoriasis at the time of screening;
✓. Patients who are deemed suitable for xeligekimab therapy by a clinician and are anticipated to receive xeligekimab treatment for the first time;
✓. Patients who are willing to sign the informed consent form.

Exclusion criteria

✕. Patients with drug-induced psoriasis (such as new-onset or exacerbated psoriasis caused by β-blockers, calcium channel blockers, or lithium);
✕. Patients with hypersensitivity to the active ingredient or any excipient in xeligekimab injection solution;
✕. Patients with other contraindications specified in the prescribing information;
✕. Patients concurrently participating in other clinical studies;
✕. Patients under other conditions or circumstances that investigators do not consider appropriate to include.

What they're measuring

Psoriasis Area and Severity Index 90 (PASI90) response rate at Week 12

Timeframe: Week 12

Trial details

NCT IDNCT06802848

SponsorChongqing Genrix Biopharmaceutical Co., Ltd

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2026-03-31

Contact for this trial

Juan Su

+86 15116408921 3694944834@qq.com

View on ClinicalTrials.gov More Plaque Psoriasis trials